Annual Lung SPORE Workshop (Abstract Submission)
75 submissions
Created | First Name | Last Name | Phone | Select a Session Topic | Abstract Title | First Author First Name | First Author Last Name | Affiliation | List of Additional Authors | Your Abstract Submission | Upload Abstract | Special Characters Included? | Abstract Review Status | Upload Poster | Poster Uploaded | Operations | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun, 03/10/2024 - 15:40 | Patrick | Oh | patrick.oh@yale.edu | Session 3: Immuno-oncology | Real-World Practice Patterns of Immunotherapy, Chemotherapy, and Targeted Therapy with Radiation Therapy in Early-Stage Node-Negative Non-Small Cell Lung Cancer | Patrick | Oh | Yale School of Medicine |
|
Abstract_Submission.pdf |
Oh_Yale_Session#3.docx16.72 KB
|
No | Approved to be a Speaker | ||||
Sun, 03/10/2024 - 14:15 | Triparna | Sen | triparna.sen@gmail.com | 9179723836 | Session 4: Small Cell Lung Cancer | Transcriptional and epigenetic landscape of neuroendocrine transformation during emergence of resistance to targeted therapies in EGFR mutant lung adenocarcinoma. | Triparna | Sen | Icahn School of Medicine at Mount Sinai | Abstract_Submission.pdf |
Sen_Mount Sinai_Session 4.docx15.01 KB
|
No | Approved to be a Poster Presenter | ||||
Sun, 03/10/2024 - 12:47 | Jessie | Hao | jessie.hao@emory.edu | 4705423594 | Session 6: Cancer Biology | Co-occurring genomic alterations-guided in silico discovery of therapeutic vulnerability in lung adenocarcinoma | Jessie | Hao | Department of Pharmacology and Chemical Biology, Emory University School of Medicine |
|
Abstract_Submission.pdf |
SPORE abstract.docx14.48 KB
|
No | Approved to be a Poster Presenter | |||
Sun, 03/10/2024 - 03:47 | Catherine | Meador | cbmeador@mgh.harvard.edu | 9192603477 | Session 4: Small Cell Lung Cancer | Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling | Catherine | Meador | Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
|
Abstract_Submission.pdf | No | Approved to be a Poster Presenter | ||||
Sat, 03/09/2024 - 14:37 | McGarry | Houghton | houghton@fredhutch.org | 2066673175 | Session 3: Immuno-oncology | Targeting the CXCR1/2 axis inhibits neutrophil function, and not recruitment, in NSCLC | Jeff | Kwak | Fred Hutch |
|
Abstract_Submission.pdf |
Houghton_FredHutch_3.docx13.61 KB
|
No | Approved to be a Speaker | |||
Sat, 03/09/2024 - 14:07 | Roger | Kim | roger.kim@pennmedicine.upenn.edu | 239-218-5328 | Session 5: Early Detection and Screening | Rationale and Design of the Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary NodulES (ARCADES) Pragmatic Randomized Controlled Trial | Roger | Kim | Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pennsylvania, Philadelphia, PA |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Sat, 03/09/2024 - 12:58 | Yuji | Shibata | yshibata@mdanderson.org | 3462274948 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Pan-HER inhibition overcomes feedback adaptation resistance to KRAS G12C inhibition in KRAS G12C mutant non-small cell lung cancer | Yuji | Shibata | Department of Thoracic Head and Neck Medical Oncology, UT M.D. Anderson Cancer Center |
|
Abstract_Submission.pdf | No | Approved to be a Poster Presenter |
|
|||
Fri, 03/08/2024 - 21:20 | Michael | Oh | michaeloh@mednet.ucla.edu | 7169829966 | Session 3: Immuno-oncology | Phase I trial of intratumoral administration of autologous CCL21 gene-modified dendritic cells combined with pembrolizumab reveals local and systemic immune activation in advanced NSCLC | Bin | Liu | UCLA |
|
Abstract_Submission.pdf |
LIU_UCLA_Session 3.docx22.94 KB
|
No | Approved to be a Poster Presenter | |||
Fri, 03/08/2024 - 19:37 | Boning | Gao | boning.gao@utsouthwestern.edu | 2146484915 | Session 6: Cancer Biology | New human cell line models for the study of pathogenesis of SARS-CoV-2 infection | Boning | Gao | UT Southwestern |
|
Abstract_Submission.pdf |
Gao_UT Southwester_Sesson#6.docx15.37 KB
|
No | Approved to be a Poster Presenter | |||
Fri, 03/08/2024 - 18:05 | Monique (Presented by Heymach) | Nilsson | mnilsson@mdanderson.org | 7137458407 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained | John | Heymach (Submitted by M. Nilsson) | MD Anderson Cancer Center |
|
Abstract_Submission.pdf | No |
![]() |
||||
Fri, 03/08/2024 - 13:42 | Shi-Yong | Sun | ssun@emory.edu | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Inhibition of hTERT/telomerase/telomere as an important mechanism mediating therapeutic efficacy of third generation EGFR inhibitors in EGFR mutant lung cancer | Zhen | Chen | Emory University |
|
Abstract_Submission.pdf | No | Approved to be a Poster Presenter | |||||
Fri, 03/08/2024 - 13:42 | Sampada | Chande | sampada.chande@yale.edu | 6097722949 | Session 6: Cancer Biology | Characterization of tumor-neuron communication in lung adenocarcinoma brain metastasis | Sampada | Chande | Department of Pathology, Yale University School of Medicine |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/04/2024 - 17:35 | Matthew | Oser | matthew_oser@dfci.harvard.edu | 9174883166 | Session 4: Small Cell Lung Cancer | Cyclin A/B RxL Macrocyclic Peptide Inhibitors as a Therapeutic Strategy for Small Cell Lung Cancers with High E2F Activity | Shilpa | Singh | Dana-Farber Cancer Institute |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Thu, 02/29/2024 - 15:57 | Bluma | Lesch | bluma.lesch@yale.edu | 203-737-1074 | Session 6: Cancer Biology | Mechanisms of epigenetic sensitization to lung cancer risk | Benjamin | Walters | Yale University |
|
Abstract_Submission.pdf |
240228_lesch_spore_abstract.docx13.43 KB
|
No | Approved to be a Poster Presenter | |||
Tue, 02/20/2024 - 09:01 | May-Lucie | Meyer | may-lucie.meyer@mssm.edu | Session 4: Small Cell Lung Cancer, Session 6: Cancer Biology | DLL3 expression in early-stage SCLC: comparative analysis of IHC and mRNA ISH | May-Lucie | Meyer | Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA |
|
Abstract_Submission.pdf | No | Approved to be a Poster Presenter |
![]() |